Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.10 Average Price Target from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received a consensus rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.10.

RXRX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Bank of America decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Morgan Stanley increased their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the sale, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Najat Khan sold 28,298 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the sale, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 96,254 shares of company stock valued at $320,369. 8.43% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of RXRX. Vanguard Group Inc. increased its position in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after buying an additional 7,407,606 shares during the last quarter. State Street Corp increased its position in Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after buying an additional 7,064,963 shares during the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth $23,473,000. ARK Investment Management LLC increased its position in Recursion Pharmaceuticals by 11.2% in the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after buying an additional 3,771,357 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Recursion Pharmaceuticals in the first quarter worth $7,370,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $3.01 on Friday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -2.51 and a beta of 1.05. The stock has a 50 day moving average of $3.28 and a 200 day moving average of $3.91. Recursion Pharmaceuticals has a 12 month low of $2.77 and a 12 month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. During the same period last year, the business posted ($0.50) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals will post -1.02 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.